{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:37:55Z","timestamp":1793165875575,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["2R01AR062587"],"award-info":[{"award-number":["2R01AR062587"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011347","name":"University of Nevada, Reno","doi-asserted-by":"publisher","award":["Hitchcock Endowed Chair in Medical Biochemistry"],"award-info":[{"award-number":["Hitchcock Endowed Chair in Medical Biochemistry"]}],"id":[{"id":"10.13039\/100011347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Renogenyx, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-57734-5","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:44:43Z","timestamp":1781603083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification of compounds that repress DUX4 expression in facioscapulohumeral muscular dystrophy"],"prefix":"10.1038","volume":"16","author":[{"given":"Ning","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah P.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis L.","family":"Himeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrence E.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baback","family":"Roshanravan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako I.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"57734_CR1","unstructured":"Padberg, G. W. Facioscapulohumeral Disease PhD thesis, Leiden University, (1982)."},{"key":"57734_CR2","unstructured":"Orphanet. Prevalence and incidence of rare diseases: Bibliographic data. Report No. Number 1: Diseases listed in alphabetical order. (2025)."},{"key":"57734_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/ng1262","volume":"35","author":"PG van Overveld","year":"2003","unstructured":"van Overveld, P. G. et al. Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat. Genet. 35, 315\u2013317. https:\/\/doi.org\/10.1038\/ng1262 (2003).","journal-title":"Nat. Genet."},{"key":"57734_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1146\/annurev-genom-083118-014933","volume":"20","author":"CL Himeda","year":"2019","unstructured":"Himeda, C. L. & Jones, P. L. The genetics and epigenetics of facioscapulohumeral muscular dystrophy. Annu. Rev. Genom. Hum. Genet. 20, 265\u2013291. https:\/\/doi.org\/10.1146\/annurev-genom-083118-014933 (2019).","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"57734_CR5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/0140-6736(90)92148-b","volume":"336","author":"C Wijmenga","year":"1990","unstructured":"Wijmenga, C. et al. Location of facioscapulohumeral muscular dystrophy gene on chromosome 4. Lancet 336, 651\u2013653. https:\/\/doi.org\/10.1016\/0140-6736(90)92148-b (1990).","journal-title":"Lancet"},{"key":"57734_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/ng0992-26","volume":"2","author":"C Wijmenga","year":"1992","unstructured":"Wijmenga, C. et al. Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat. Genet. 2, 26\u201330. https:\/\/doi.org\/10.1038\/ng0992-26 (1992).","journal-title":"Nat. Genet."},{"key":"57734_CR7","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1093\/hmg\/2.12.2037","volume":"2","author":"JC van Deutekom","year":"1993","unstructured":"van Deutekom, J. C. et al. FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum. Mol. Genet. 2, 2037\u20132042. https:\/\/doi.org\/10.1093\/hmg\/2.12.2037 (1993).","journal-title":"Hum. Mol. Genet."},{"key":"57734_CR8","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ng.2454","volume":"44","author":"RJ Lemmers","year":"2012","unstructured":"Lemmers, R. J. et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat. Genet. 44, 1370\u20131374. https:\/\/doi.org\/10.1038\/ng.2454 (2012).","journal-title":"Nat. Genet."},{"key":"57734_CR9","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.ajhg.2016.03.013","volume":"98","author":"ML van den Boogaard","year":"2016","unstructured":"van den Boogaard, M. L. et al. Mutations in DNMT3B modify epigenetic repression of the D4Z4 repeat and the penetrance of facioscapulohumeral dystrophy. Am. J. Hum. Genet. 98, 1020\u20131029. https:\/\/doi.org\/10.1016\/j.ajhg.2016.03.013 (2016).","journal-title":"Am. J. Hum. Genet."},{"key":"57734_CR10","doi-asserted-by":"publisher","first-page":"e2441","DOI":"10.1212\/WNL.0000000000009617","volume":"94","author":"K Hamanaka","year":"2020","unstructured":"Hamanaka, K. et al. Homozygous nonsense variant in LRIF1 associated with facioscapulohumeral muscular dystrophy. Neurology 94, e2441\u2013e2447. https:\/\/doi.org\/10.1212\/WNL.0000000000009617 (2020).","journal-title":"Neurology"},{"key":"57734_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1001181","volume":"6","author":"L Snider","year":"2010","unstructured":"Snider, L. et al. Facioscapulohumeral dystrophy: Incomplete suppression of a retrotransposed gene. PLoS Genet. 6, e1001181. https:\/\/doi.org\/10.1371\/journal.pgen.1001181 (2010).","journal-title":"PLoS Genet."},{"key":"57734_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1582-4934.2012.01647.x","volume":"17","author":"A Tassin","year":"2013","unstructured":"Tassin, A. et al. DUX4 expression in FSHD muscle cells: How could such a rare protein cause a myopathy?. J. Cell Mol. Med. 17, 76\u201389. https:\/\/doi.org\/10.1111\/j.1582-4934.2012.01647.x (2013).","journal-title":"J. Cell Mol. Med."},{"key":"57734_CR13","doi-asserted-by":"publisher","first-page":"R153","DOI":"10.1093\/hmg\/ddy162","volume":"27","author":"AE Campbell","year":"2018","unstructured":"Campbell, A. E., Belleville, A. E., Resnick, R., Shadle, S. C. & Tapscott, S. J. Facioscapulohumeral dystrophy: Activating an early embryonic transcriptional program in human skeletal muscle. Hum. Mol. Genet. 27, R153\u2013R162. https:\/\/doi.org\/10.1093\/hmg\/ddy162 (2018).","journal-title":"Hum. Mol. Genet."},{"key":"57734_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s0378-1119(99)00267-x","volume":"236","author":"J Gabriels","year":"1999","unstructured":"Gabriels, J. et al. Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. Gene 236, 25\u201332. https:\/\/doi.org\/10.1016\/s0378-1119(99)00267-x (1999).","journal-title":"Gene"},{"key":"57734_CR15","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1126\/science.1189044","volume":"329","author":"RJ Lemmers","year":"2010","unstructured":"Lemmers, R. J. et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 329, 1650\u20131653. https:\/\/doi.org\/10.1126\/science.1189044 (2010).","journal-title":"Science"},{"key":"57734_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12060865","author":"CL Himeda","year":"2022","unstructured":"Himeda, C. L. & Jones, P. L. FSHD therapeutic strategies: What will it take to get to clinic?. J. Pers. Med. https:\/\/doi.org\/10.3390\/jpm12060865 (2022).","journal-title":"J. Pers. Med."},{"key":"57734_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11010007","author":"R Joubert","year":"2020","unstructured":"Joubert, R., Mariot, V., Charpentier, M., Concordet, J. P. & Dumonceaux, J. Gene editing targeting the DUX4 polyadenylation signal: A therapy for FSHD?. J. Pers. Med. https:\/\/doi.org\/10.3390\/jpm11010007 (2020).","journal-title":"J. Pers. Med."},{"key":"57734_CR18","doi-asserted-by":"publisher","first-page":"12598","DOI":"10.1038\/s41598-021-92096-0","volume":"11","author":"S Das","year":"2021","unstructured":"Das, S. & Chadwick, B. P. CRISPR mediated targeting of DUX4 distal regulatory element represses DUX4 target genes dysregulated in Facioscapulohumeral muscular dystrophy. Sci. Rep. 11, 12598. https:\/\/doi.org\/10.1038\/s41598-021-92096-0 (2021).","journal-title":"Sci. Rep."},{"key":"57734_CR19","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.omtn.2021.05.020","volume":"25","author":"D Sikrova","year":"2021","unstructured":"Sikrova, D. et al. Adenine base editing of the DUX4 polyadenylation signal for targeted genetic therapy in facioscapulohumeral muscular dystrophy. Mol. Ther. Nucleic Acids 25, 342\u2013354. https:\/\/doi.org\/10.1016\/j.omtn.2021.05.020 (2021).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"57734_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101546","volume":"33","author":"CL Himeda","year":"2025","unstructured":"Himeda, C. L., Jones, T. I. & Jones, P. L. All-in-one vectors for epigenetic CRISPR inhibition of DUX4-fl in facioscapulohumeral muscular dystrophy. Mol. Ther. Methods Clin. Dev. 33, 101546. https:\/\/doi.org\/10.1016\/j.omtm.2025.101546 (2025).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"57734_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25169065","author":"SL Beck","year":"2024","unstructured":"Beck, S. L. & Yokota, T. Oligonucleotide therapies for facioscapulohumeral muscular dystrophy: Current preclinical landscape. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms25169065 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"57734_CR22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1124\/jpet.119.264689","volume":"374","author":"LA Rojas","year":"2020","unstructured":"Rojas, L. A. et al. p38alpha regulates expression of DUX4 in a model of facioscapulohumeral muscular dystrophy. J. Pharmacol. Exp. Ther. 374, 489\u2013498. https:\/\/doi.org\/10.1124\/jpet.119.264689 (2020).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"57734_CR23","doi-asserted-by":"publisher","first-page":"4658","DOI":"10.1111\/bcp.14884","volume":"87","author":"ML Mellion","year":"2021","unstructured":"Mellion, M. L. et al. Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement. Br. J. Clin. Pharmacol. 87, 4658\u20134669. https:\/\/doi.org\/10.1111\/bcp.14884 (2021).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"57734_CR24","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.mce.2006.03.017","volume":"252","author":"A Keren","year":"2006","unstructured":"Keren, A., Tamir, Y. & Bengal, E. The p38 MAPK signaling pathway: A major regulator of skeletal muscle development. Mol. Cell Endocrinol. 252, 224\u2013230. https:\/\/doi.org\/10.1016\/j.mce.2006.03.017 (2006).","journal-title":"Mol. Cell Endocrinol."},{"key":"57734_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fcell.2016.00091","volume":"4","author":"J Segales","year":"2016","unstructured":"Segales, J., Perdiguero, E. & Munoz-Canoves, P. Regulation of muscle stem cell functions: A focus on the p38 MAPK signaling pathway. Front. Cell Dev. Biol. 4, 91. https:\/\/doi.org\/10.3389\/fcell.2016.00091 (2016).","journal-title":"Front. Cell Dev. Biol."},{"key":"57734_CR26","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/j.ymthe.2018.04.019","volume":"26","author":"CL Himeda","year":"2018","unstructured":"Himeda, C. L. et al. Identification of epigenetic regulators of DUX4-fl for targeted therapy of facioscapulohumeral muscular dystrophy. Mol. Ther. 26, 1797\u20131807. https:\/\/doi.org\/10.1016\/j.ymthe.2018.04.019 (2018).","journal-title":"Mol. Ther."},{"key":"57734_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/s0092-8674(00)80321-9","volume":"90","author":"T Ito","year":"1997","unstructured":"Ito, T., Bulger, M., Pazin, M. J., Kobayashi, R. & Kadonaga, J. T. ACF, an ISWI-containing and ATP-utilizing chromatin assembly and remodeling factor. Cell 90, 145\u2013155. https:\/\/doi.org\/10.1016\/s0092-8674(00)80321-9 (1997).","journal-title":"Cell"},{"key":"57734_CR28","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/nature08621","volume":"462","author":"LR Racki","year":"2009","unstructured":"Racki, L. R. et al. The chromatin remodeller ACF acts as a dimeric motor to space nucleosomes. Nature 462, 1016\u20131021. https:\/\/doi.org\/10.1038\/nature08621 (2009).","journal-title":"Nature"},{"key":"57734_CR29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1146\/annurev.biochem.77.062706.153223","volume":"78","author":"CR Clapier","year":"2009","unstructured":"Clapier, C. R. & Cairns, B. R. The biology of chromatin remodeling complexes. Annu. Rev. Biochem. 78, 273\u2013304. https:\/\/doi.org\/10.1146\/annurev.biochem.77.062706.153223 (2009).","journal-title":"Annu. Rev. Biochem."},{"key":"57734_CR30","doi-asserted-by":"publisher","unstructured":"Wallach, I., Dzamba, M. & Heifets, A. AtomNet: A Deep Convolutional Neural Network for Bioactivity Prediction in Structure-based Drug Discovery. Preprint at https:\/\/doi.org\/10.48550\/arXiv.41510.02855 (2015).","DOI":"10.48550\/arXiv.41510.02855"},{"key":"57734_CR31","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1038\/emboj.2008.201","volume":"27","author":"D Bosnakovski","year":"2008","unstructured":"Bosnakovski, D. et al. An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies. EMBO J. 27, 2766\u20132779. https:\/\/doi.org\/10.1038\/emboj.2008.201 (2008).","journal-title":"EMBO J."},{"key":"57734_CR32","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.1021\/jm030121k","volume":"46","author":"J Regan","year":"2003","unstructured":"Regan, J. et al. Structure-activity relationships of the p38\u03b1 MAP kinase inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796). J. Med. Chem. 46, 4676\u20134686. https:\/\/doi.org\/10.1021\/jm030121k (2003).","journal-title":"J. Med. Chem."},{"key":"57734_CR33","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.53689","author":"LL Arnold","year":"2020","unstructured":"Arnold, L. L. et al. EphA7 promotes myogenic differentiation via cell-cell contact. Elife https:\/\/doi.org\/10.7554\/eLife.53689 (2020).","journal-title":"Elife"},{"key":"57734_CR34","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1634\/stemcells.2008-0826","volume":"27","author":"DC Andersen","year":"2009","unstructured":"Andersen, D. C. et al. Characterization of DLK1+ cells emerging during skeletal muscle remodeling in response to myositis, myopathies, and acute injury. Stem Cells 27, 898\u2013908. https:\/\/doi.org\/10.1634\/stemcells.2008-0826 (2009).","journal-title":"Stem Cells"},{"key":"57734_CR35","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.11405","author":"LA Moyle","year":"2016","unstructured":"Moyle, L. A. et al. Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy. Elife https:\/\/doi.org\/10.7554\/eLife.11405 (2016).","journal-title":"Elife"},{"key":"57734_CR36","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.18351","author":"J Shin","year":"2016","unstructured":"Shin, J. et al. BRAF activates PAX3 to control muscle precursor cell migration during forelimb muscle development. Elife https:\/\/doi.org\/10.7554\/eLife.18351 (2016).","journal-title":"Elife"},{"key":"57734_CR37","doi-asserted-by":"publisher","first-page":"13193","DOI":"10.1074\/jbc.M809038200","volume":"284","author":"S Han","year":"2009","unstructured":"Han, S. et al. Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor design. J. Biol. Chem. 284, 13193\u201313201. https:\/\/doi.org\/10.1074\/jbc.M809038200 (2009).","journal-title":"J. Biol. Chem."},{"key":"57734_CR38","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1124\/jpet.119.259663","volume":"370","author":"J Oliva","year":"2019","unstructured":"Oliva, J. et al. Clinically advanced p38 inhibitors suppress DUX4 expression in cellular and animal models of facioscapulohumeral muscular dystrophy. J. Pharmacol. Exp. Ther. 370, 219\u2013230. https:\/\/doi.org\/10.1124\/jpet.119.259663 (2019).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"57734_CR39","doi-asserted-by":"publisher","first-page":"26437","DOI":"10.1038\/s41598-024-77911-8","volume":"14","author":"R Vangipurapu","year":"2024","unstructured":"Vangipurapu, R., Oliva, J., Fox, A. & Sverdrup, F. M. Temporal variation in p38-mediated regulation of DUX4 in facioscapulohumeral muscular dystrophy. Sci. Rep. 14, 26437. https:\/\/doi.org\/10.1038\/s41598-024-77911-8 (2024).","journal-title":"Sci. Rep."},{"key":"57734_CR40","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.omtm.2020.12.001","volume":"20","author":"CL Himeda","year":"2021","unstructured":"Himeda, C. L., Jones, T. I. & Jones, P. L. Targeted epigenetic repression by CRISPR\/dSaCas9 suppresses pathogenic DUX4-fl expression in FSHD. Mol. Ther. Methods Clin. Dev. 20, 298\u2013311. https:\/\/doi.org\/10.1016\/j.omtm.2020.12.001 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"57734_CR41","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S1474-4422(24)00073-5","volume":"23","author":"R Tawil","year":"2024","unstructured":"Tawil, R. et al. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): A randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol. 23, 477\u2013486. https:\/\/doi.org\/10.1016\/S1474-4422(24)00073-5 (2024).","journal-title":"Lancet Neurol."},{"key":"57734_CR42","doi-asserted-by":"publisher","DOI":"10.1177\/22143602261419558","author":"NC Voermans","year":"2026","unstructured":"Voermans, N. C. et al. A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study. J. Neuromuscul. Dis. https:\/\/doi.org\/10.1177\/22143602261419558 (2026).","journal-title":"J. Neuromuscul. Dis."},{"key":"57734_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2025.105422","volume":"52","author":"RJ Bloch","year":"2025","unstructured":"Bloch, R. J., Traficante, M., Mariot, V. & Dumonceaux, J. The recent clinical trial of losmapimod for the treatment of facioscapulohumeral muscular dystrophy. Neuromuscul. Disord. 52, 105422. https:\/\/doi.org\/10.1016\/j.nmd.2025.105422 (2025).","journal-title":"Neuromuscul. Disord."},{"key":"57734_CR44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.bbrc.2021.04.004","volume":"557","author":"TY Kim","year":"2021","unstructured":"Kim, T. Y., Kang, J. H., Lee, S. B., Kang, T. B. & Lee, K. H. Down-regulation of pro-necroptotic molecules blunts necroptosis during myogenesis. Biochem. Biophys. Res. Commun. 557, 33\u201339. https:\/\/doi.org\/10.1016\/j.bbrc.2021.04.004 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"57734_CR45","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1002\/jcsm.12813","volume":"12","author":"V Mariot","year":"2021","unstructured":"Mariot, V. et al. RIPK3-mediated cell death is involved in DUX4-mediated toxicity in facioscapulohumeral dystrophy. J. Cachexia Sarcopenia Muscle 12, 2079\u20132090. https:\/\/doi.org\/10.1002\/jcsm.12813 (2021).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"57734_CR46","doi-asserted-by":"publisher","first-page":"4419","DOI":"10.1093\/hmg\/dds284","volume":"21","author":"TI Jones","year":"2012","unstructured":"Jones, T. I. et al. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: Evidence for disease modifiers and a quantitative model of pathogenesis. Hum. Mol. Genet. 21, 4419\u20134430. https:\/\/doi.org\/10.1093\/hmg\/dds284 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"57734_CR47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13148-015-0072-6","volume":"7","author":"TI Jones","year":"2015","unstructured":"Jones, T. I. et al. Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy. Clin. Epigenet. 7, 37. https:\/\/doi.org\/10.1186\/s13148-015-0072-6 (2015).","journal-title":"Clin. Epigenet."},{"key":"57734_CR48","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/mt.2015.200","volume":"24","author":"CL Himeda","year":"2016","unstructured":"Himeda, C. L., Jones, T. I. & Jones, P. L. CRISPR\/dCas9-mediated transcriptional inhibition ameliorates the epigenetic dysregulation at D4Z4 and represses DUX4-fl in FSH muscular dystrophy. Mol. Ther. 24, 527\u2013535. https:\/\/doi.org\/10.1038\/mt.2015.200 (2016).","journal-title":"Mol. Ther."},{"key":"57734_CR49","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.31023","author":"AE Campbell","year":"2018","unstructured":"Campbell, A. E. et al. NuRD and CAF-1-mediated silencing of the D4Z4 array is modulated by DUX4-induced MBD3L proteins. Elife https:\/\/doi.org\/10.7554\/eLife.31023 (2018).","journal-title":"Elife"},{"key":"57734_CR50","unstructured":"The FSHD Research Center at UR Medicine. Protocols and Procedures, https:\/\/www.urmc.rochester.edu\/neurology\/fshd-center\/research-info\/protocols Accessed 13 March 2026."},{"key":"57734_CR51","doi-asserted-by":"publisher","first-page":"e1384","DOI":"10.1212\/WNL.0000000000200032","volume":"98","author":"P Mohassel","year":"2022","unstructured":"Mohassel, P. et al. Cross-sectional neuromuscular phenotyping study of patients with arhinia with SMCHD1 variants. Neurology 98, e1384\u2013e1396. https:\/\/doi.org\/10.1212\/WNL.0000000000200032 (2022).","journal-title":"Neurology"},{"key":"57734_CR52","doi-asserted-by":"publisher","first-page":"7526","DOI":"10.1038\/s41598-024-54655-z","volume":"14","author":"I Wallach","year":"2024","unstructured":"Wallach, I. et al. AI is a viable alternative to high throughput screening: A 318-target study. Sci. Rep. 14, 7526. https:\/\/doi.org\/10.1038\/s41598-024-54655-z (2024).","journal-title":"Sci. Rep."},{"key":"57734_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127745","volume":"33","author":"Z Yang","year":"2021","unstructured":"Yang, Z., Zhou, Y. & Zhong, L. Discovery of BAZ1A bromodomain inhibitors with the aid of virtual screening and activity evaluation. Bioorg. Med. Chem. Lett. 33, 127745. https:\/\/doi.org\/10.1016\/j.bmcl.2020.127745 (2021).","journal-title":"Bioorg. Med. Chem. Lett."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57734-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57734-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57734-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:19:45Z","timestamp":1788304785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57734-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["57734"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-57734-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CLH, TIJ, and PLJ are cofounders, shareholders, and members of the board of directors of Renogenyx, Inc., a company focused on bringing FSHD therapeutics to the clinic, and inventors on four international patent applications pertaining to the use of CRISPR inhibition for FSHD (WO\/2024\/020444, WO\/2021\/211325, WO\/2025\/019820) or muscle-specific regulatory cassettes for NMDs (WO\/2024\/020444).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27471"}}